Gemtuzumab

From Ganfyd

Jump to: navigation, search

Contents

Introduction

In development targeted at CD33+ive acute myeloid leukaemia.

Clinical Use

Indications

Administration

IV

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

  • Prolonged severe bone marrow suppression
  • Hepatoxicity
  • Chills, fever and hypotension at time of infusion

Special advice

Pharmacology

When the antibody attaches to CD33, the cells absorb the antibody and its cytotoxic attachment calicheamicin. Calicheamicin on release into the cytosol breaks up the DNA.

Personal tools